[go: up one dir, main page]

FR2786771B1 - Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose - Google Patents

Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose

Info

Publication number
FR2786771B1
FR2786771B1 FR9915256A FR9915256A FR2786771B1 FR 2786771 B1 FR2786771 B1 FR 2786771B1 FR 9915256 A FR9915256 A FR 9915256A FR 9915256 A FR9915256 A FR 9915256A FR 2786771 B1 FR2786771 B1 FR 2786771B1
Authority
FR
France
Prior art keywords
stabilizing
poly
compound
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9915256A
Other languages
English (en)
Other versions
FR2786771A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2786771(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2786771A1 publication Critical patent/FR2786771A1/fr
Application granted granted Critical
Publication of FR2786771B1 publication Critical patent/FR2786771B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FR9915256A 1998-12-07 1999-12-03 Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose Expired - Lifetime FR2786771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (2)

Publication Number Publication Date
FR2786771A1 FR2786771A1 (fr) 2000-06-09
FR2786771B1 true FR2786771B1 (fr) 2002-12-27

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9915256A Expired - Lifetime FR2786771B1 (fr) 1998-12-07 1999-12-03 Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose

Country Status (38)

Country Link
US (5) US6605613B2 (fr)
EP (4) EP1743657A3 (fr)
JP (3) JP3805625B2 (fr)
KR (2) KR20060096477A (fr)
CN (2) CN1261163C (fr)
AR (3) AR026102A1 (fr)
AT (1) ATE365051T1 (fr)
AU (1) AU759219B2 (fr)
BE (1) BE1012869A3 (fr)
BR (1) BR9915986A (fr)
CA (3) CA2732620C (fr)
CO (1) CO4980847A1 (fr)
CY (1) CY1106870T1 (fr)
CZ (2) CZ303006B6 (fr)
DE (1) DE69936352T3 (fr)
DK (1) DK1137439T4 (fr)
ES (1) ES2288033T5 (fr)
FR (1) FR2786771B1 (fr)
GB (2) GB9826882D0 (fr)
HK (1) HK1038889B (fr)
HU (2) HU228939B1 (fr)
ID (1) ID29250A (fr)
IL (1) IL143092A0 (fr)
IT (1) IT1319701B1 (fr)
MY (2) MY120594A (fr)
NO (2) NO332698B1 (fr)
NZ (2) NZ511936A (fr)
PE (1) PE20001333A1 (fr)
PL (2) PL208854B1 (fr)
PT (1) PT1137439E (fr)
RU (1) RU2243769C2 (fr)
SG (1) SG151072A1 (fr)
SI (1) SI1137439T2 (fr)
SK (2) SK287325B6 (fr)
TR (2) TR200201428T2 (fr)
TW (2) TWI248938B (fr)
WO (1) WO2000033878A2 (fr)
ZA (1) ZA200104360B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CA2475383C (fr) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Procede d'extraction d'un macrolide a partir d'une matiere biologique
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
DE04758730T1 (de) * 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005010015A1 (fr) 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Procede de purification de macrolides
WO2005027906A1 (fr) 2003-09-18 2005-03-31 Macusight, Inc. Administration transsclerale d'agents therapeutiques
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2548596A1 (fr) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Methode de traitement d'un effet indesirable suite a la liberation d'un medicament au niveau transdermique ou topique
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006039237A1 (fr) * 2004-09-29 2006-04-13 Cordis Corporation Formes posologiques pharmaceutiques de composes amorphes stables semblables a la rapamycine
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
WO2007075621A1 (fr) * 2005-12-20 2007-07-05 Wyeth Maitrise de la stabilite de la forme pharmaceutique de cci-779 par l'elimination optimale des impuretes de la substance medicamenteuse
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CA2797501A1 (fr) * 2010-06-07 2011-12-15 Telik, Inc. Chlorhydrate d'ezatiostat non solvate cristallise
EP2601201B1 (fr) * 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Procédé pour la préparation des composés nouveaux du 42-o-(hétéroalkyloxy) rapamycin avec les propriétaires antiprolifiques.
WO2012066502A1 (fr) 2010-11-19 2012-05-24 Biocon Limited Procédés de préparation d'évérolimus et d'intermédiaires de celui-ci
EP2717884A1 (fr) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Utilisation de composés métallocènes pour le traitement du cancer
WO2013022201A1 (fr) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Procédé de préparation d'une formulation stabilisée et solubilisée de dérivés de sirolimus
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (fr) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
EP3342410A4 (fr) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha Composition pharmaceutique contenant de la rapamycine ou un dérivé de celle-ci
WO2017047618A1 (fr) * 2015-09-18 2017-03-23 日本化薬株式会社 Composition médicamenteuse comprenant de la rapamycine ou un dérivé de celle-ci
WO2017129772A1 (fr) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Compositions pharmaceutiques stables de temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DK0593227T3 (da) 1992-10-13 2006-05-01 Wyeth Corp Carbamater af rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ES2182112T3 (es) * 1996-07-30 2003-03-01 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
AU6041498A (en) 1997-02-04 1998-08-25 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
PE20001333A1 (es) 2000-12-12
GB9826882D0 (en) 1999-01-27
MY120594A (en) 2005-11-30
BE1012869A3 (fr) 2001-04-03
HUP0104489A3 (en) 2004-05-28
US20050107418A1 (en) 2005-05-19
DK1137439T4 (da) 2012-03-19
CA2351580C (fr) 2012-03-20
CZ20012001A3 (cs) 2001-09-12
IT1319701B1 (it) 2003-10-27
CN1876657A (zh) 2006-12-13
CZ302210B6 (cs) 2010-12-22
EP1743657A2 (fr) 2007-01-17
NZ511936A (en) 2003-10-31
DE69936352T2 (de) 2008-02-14
AU1657300A (en) 2000-06-26
SI1137439T2 (sl) 2012-05-31
ES2288033T3 (es) 2007-12-16
BR9915986A (pt) 2001-09-04
CZ303006B6 (cs) 2012-02-22
JP3805625B2 (ja) 2006-08-02
US6852729B2 (en) 2005-02-08
ZA200104360B (en) 2002-01-16
EP2269651A3 (fr) 2011-03-09
AR048073A2 (es) 2006-03-29
US6605613B2 (en) 2003-08-12
ATE365051T1 (de) 2007-07-15
SK287325B6 (sk) 2010-07-07
CN1876657B (zh) 2013-01-09
PL348333A1 (en) 2002-05-20
KR100695834B1 (ko) 2007-03-19
PT1137439E (pt) 2007-09-25
CA2651609A1 (fr) 2000-06-15
WO2000033878A2 (fr) 2000-06-15
EP2269651A2 (fr) 2011-01-05
TWI270550B (en) 2007-01-11
RU2243769C2 (ru) 2005-01-10
CA2351580A1 (fr) 2000-06-15
EP1743657A3 (fr) 2007-03-28
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
CO4980847A1 (es) 2000-11-27
TR200101416T2 (tr) 2002-01-21
EP2279751A2 (fr) 2011-02-02
ITMI992520A1 (it) 2001-06-02
US20030191148A1 (en) 2003-10-09
US7297703B2 (en) 2007-11-20
NO20012424L (no) 2001-05-16
US20020032213A1 (en) 2002-03-14
SI1137439T1 (sl) 2008-06-30
US20080161334A1 (en) 2008-07-03
HU230174B1 (hu) 2015-09-28
JP2005200429A (ja) 2005-07-28
SK286688B6 (sk) 2009-03-05
IL143092A0 (en) 2002-04-21
EP2279751A3 (fr) 2011-02-16
EP1137439A2 (fr) 2001-10-04
AU759219B2 (en) 2003-04-10
HU228939B1 (en) 2013-07-29
ITMI992520A0 (it) 1999-12-02
GB9904934D0 (en) 1999-04-28
JP2006111637A (ja) 2006-04-27
JP5165199B2 (ja) 2013-03-21
US7741338B2 (en) 2010-06-22
DE69936352D1 (de) 2007-08-02
NO20121113L (no) 2001-05-16
HK1038889B (en) 2008-01-25
TR200201428T2 (tr) 2002-12-23
PL208854B1 (pl) 2011-06-30
CA2732620A1 (fr) 2000-06-15
EP1137439B1 (fr) 2007-06-20
NZ527781A (en) 2004-11-26
WO2000033878A3 (fr) 2000-11-02
KR20060096477A (ko) 2006-09-11
US20090270441A1 (en) 2009-10-29
CA2732620C (fr) 2013-08-06
EP1137439B2 (fr) 2011-11-23
PL196627B1 (pl) 2008-01-31
HUP0104489A2 (hu) 2002-03-28
MY127579A (en) 2006-12-29
NO334612B1 (no) 2014-04-22
KR20010101128A (ko) 2001-11-14
JP5043308B2 (ja) 2012-10-10
DE69936352T3 (de) 2012-05-03
TWI248938B (en) 2006-02-11
AR054444A2 (es) 2007-06-27
SK7662001A3 (en) 2001-12-03
NO332698B1 (no) 2012-12-10
US7572804B2 (en) 2009-08-11
JP2002531527A (ja) 2002-09-24
CN1261163C (zh) 2006-06-28
NO20012424D0 (no) 2001-05-16
TW200540179A (en) 2005-12-16
AR026102A1 (es) 2003-01-29
CN1374872A (zh) 2002-10-16
SG151072A1 (en) 2009-06-29
ES2288033T5 (es) 2012-04-10
FR2786771A1 (fr) 2000-06-09
HK1038889A1 (en) 2002-04-04
ID29250A (id) 2001-08-16

Similar Documents

Publication Publication Date Title
FR2786771B1 (fr) Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose
CZ99396A3 (en) Macrolide compounds and pharmaceutical composition containing thereof
IL105715A0 (en) 7beta substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions containing them
MA24832A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydropyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
FR2670488B1 (fr) Composition pharmaceutique contenant une forme physique particuliere d'un amide heterocyclique et son procede de preparation.
AU6613996A (en) Heterocyclic compounds and pharmaceutical compositions containing them
FR2738834B1 (fr) Composition de polyolefine stabilisee et procede de stabilisation d'articles moules en polyolefine
HUP9901150A3 (en) Pharmaceutical composition for bacterial inhibition containing an oligosaccharide compound
HUP9900467A3 (en) Novel acid-labile pharmaceutical composition containing omeprazole and process for its preparation
IL117237A0 (en) Pharmaceutical composition for piperidinoalkanol compounds
DZ2538A1 (fr) Tartrate d'un dipeptide substitué procédé pour sa préparation et compositions pharmaceutiques le contenant.
ZA962916B (en) New arylglycineamide derivatives processes for the manufacture thereof and pharmaceutical compositions containing these compounds
AU4513393A (en) Pharmaceutical composition containing antiulcer agent
IL105717A0 (en) 7beta substituted-4-aza-5alpha-cholestan-3-ones and pharmaceutical compositions containing them
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
IL118426A0 (en) Pharmaceutical composition containing 1,3-bis-triazolyl-2- propanol derivative
MA26581A1 (fr) Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant
DE69631609D1 (en) Tricyclische erythromycinderivate
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
PL301281A1 (en) Novel organic compounds, method of obtaining such novel compounds and pharmaceutical composition containing them
FR2767694B1 (fr) Systeme a base de derive d'acide phosphonique et de metabisulfite pour stabiliser l'acide ascorbique et composition contenant un tel systeme
DZ2680A1 (fr) Dérivé de thiazolidinedione nouveau procédé pour sa préparation et composition pharmaceutique le contenant.
HU9402187D0 (en) Heterocyclic compounds, process for producing them and pharmaceutical compositions containing them
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
AU5754794A (en) New (aryl(alkyl)carbonyl)-heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20